SynthesisJournal of orthopaedic surgery and research2026
Safety and clinical efficacy of topical TXA in orthopedic trauma surgery: a systematic review and meta analysis.
Synthesis in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerioperative blood loss remains a major challenge in orthopedic trauma surgery, often necessitating transfusions and associated risks. Tranexamic acid (TXA), an antifibrinolytic agent, is increasingly used to minimize bleeding, yet the role of topical TXA in trauma surgery is less clearly defined.
methodsA systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. Randomized controlled trials comparing topical tranexamic acid (TXA) with placebo or comparators in orthopedic trauma surgery were identified through searches of PubMed, MEDLINE, EMBASE, CENTRAL, WHO ICTRP, and ISRCTN up to April 5, 2025. Two.reviewers independently screened, extracted data, and assessed quality using ROB2 and ROBINS-I tools. Outcomes included total blood loss, intra operative blood loss, post operative blood loss, hidden blood loss, transfusion rates, complications, overall mortality, and operation time. Data were pooled in RevMan 5.4 using random-effects models, with heterogeneity assessed by χ
resultsFourteen studies involving 1497 patients were included in the analysis. Topical TXA reduced postoperative blood loss ( p < 0.00001) and total blood loss ( p < 0.00001). Transfusion requirements were consistently lower in the TXA groups ( p = 0.004 ). No significant reduction in hidden blood loss ( p = 0.06) intra operative blood loss ( p = 0.09 ) and hospital stay ( p = 0.07 ) was observed compared to placebo or standard care. No significant increase in operation time ( p = 0.10 ), complications ( p = 0.75 ), or short-term mortality was observed ( p = 0.07 ) .
conclusionTopical TXA is a safe and effective method for reducing perioperative blood loss and transfusion needs in orthopedic trauma surgery. While current evidence supports its routine use, further large-scale, multicenter trials with standardized dosing protocols are warranted to confirm longterm safety and establish optimal administration regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.